A rare cause of hypoglycaemia by Sciberras, Robert
Malta Medical Journal    Volume 22   Issue 03   2010 21
Case Report
A rare cause of hypoglycaemia
Robert Sciberras
Abstract
This paper describes a case study concerning a young man on 
treatment for psychiatric illness who developed severe episodes 
of hypoglycaemia. After several investigations, lithium therapy 
was implicated. Stopping this treatment resulted in the patient 
being relieved of these episodes.
A rare cause of hypoglycaemia
F.A. is a 36 year old male health care worker with a long-
standing history of psychiatric illnesses and repeated admissions 
to the Psychiatric Short-Stay Ward. The depressive illness was 
precipitated by an accident in a previous work-place. Other past 
history included hypertension of 4 years duration and spinal 
surgery for a prolapsed disc in 2006.
The patient is married to a diabetic lady, who is on gliclazide 
and metformin. She monitors her own blood glucose at home 
using a glucose meter.
F.A. was referred in October 2008 complaining of recurrent 
hypoglycamic attacks occurring approximately every 2 days 
for the past 4 weeks. The low glucose levels ranging between 
2.2mmol/L and 2.7mmol/L were documented by his wife using 
her glucose meter. The hypoglycaemic attacks were typical and 
included excessive sweating, tremors, nausea and at times, 
episodes of confusion. The episodes were relieved by the patient 
ingesting a large bar of chocolate followed by sugary drinks. 
The patient was on clozapine 25mg, ½ tablet three times a 
day, lithium 400mg tabs, 600mg at night, mianserin 10mg, two 
tablets three times a day and paroxetine 20mg two tablets in the 
morning and one tablet in the evening. His blood pressure was 
well controlled with amlodipine 5mg once daily. 
There were no other systemic complaints, and no relevant 
family history. There was no recent change in appetite or weight. 
Examination was unremarkable. Given his work-place and also 
his home situation, surreptitious ingestion of oral hypoglycaemic 
agents was suspected but subsequently eliminated as the 
cause for his attacks. At his place of work he did not have 
access to any hypoglycaemic agents. At home, his wife kept 
her medications under lock and key particularly because the 
couple had two small children. She could also account for all 
her tablets. Psychiatric consultation concerning whether any 
of the psychiatric medications could be causing hypoglycaemia 
proved negative. All investigations including thyroid function 
tests were normal. Serum lithium level was 0.45mmol/L (normal 
range 0.6-1.2mmol/L). The patients did not present a history 
of lithium toxicity.
The patient was admitted to Gozo General Hospital for 
monitoring at the end of October 2008. During admission two 
hypoglycaemic attacks occurred and were witnessed by the 
author. The glucose levels were 2.6mmol/L and 2.7mmol/L 
respectively. The hypoglycaemic attacks had to be aborted 
rapidly by dextrose infusion as the patient became very 
symptomatic, confused and on the point of becoming aggressive. 
Blood tests were taken during the hypoglycaemia: C-Peptide 
level was 5.85ng/ml (normal range is 0.80-4.00ng/ml), insulin 
level was 31.0microU/ml (normal range 2.0-25.0microU/
ml), and proinsulin level was 88pmol/L (normal range is 
6.4-9.4pmol/L). These levels were inappropriately high for a 
patient with hypoglycaemia. 
An insulinoma was suspected and an urgent computerised 
axial tomography of the abdomen was carried out, including 
1.5mm slices at the pancreatic level. This was reported as 
normal.
Meanwhile hypoglycaemic episodes were still occurring in 
spite of continuous dextrose infusion and so the patient was 
started on prednisolone 10mg three times a day. This medication 
put an end to the hypoglycaemic episodes and the patient was 
discharged home pending further investigations. 
An Indium-111 octreotide scintigraphy was performed on the 
17th of December 2008, 4 hours and 24 hours following intravenous 
administration of 160MBq of Octreoscan. Both whole body and 
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SPECT images were acquired. There was no abnormal focus of 
tracer accumulated in the abdomen. Physiological activity was 
seen in liver, spleen and kidneys with intestinal activity evident 
at 24 hours. It was therefore concluded that there was no definite 
evidence of insulinoma. However sensitivity of octreotide 
scintigraphy is in the range of only 50% (see discussion below). 
Surgical consultation resulted in the patient being scheduled 
for exploratory laparotomy which might have included total 
pancreatectomy. At the eleventh hour the surgery was postponed 
due to repeated hypoglycaemic episodes. During one of these 
episodes, blood investigations showed an insulin level of 
22microU/ml (reference range 2.0-25.0microU/ml), C-peptide 
level of 3.64ng/ml (reference range 0.80-4.00ng/ml), and 
proinsulin level of 30.4pmol/L (reference range 6.4-9.4pmol/L). 
The patient was started on diazoxide 50mg, four tablets three 
times a day and discharged home on the 10th of March 2009.
Two days later the patient was admitted urgently to hospital 
complaining of fever of 102 degrees Fahrenheit, severe muscle 
aches and pains, shortness of breath and inability to walk due 
to generalized weakness and stiffness. There was no wheezing 
or rash. His eosinophil count was normal. The symptoms 
had started on initiating diazoxide therapy. A reaction to 
the medication was suspected, the drug withdrawn and all 
symptoms resolved. At this point, lithium therapy started to 
be suspected to be causing the hypoglycaemic episodes in this 
patient. The dose of lithium was reduced to 400mg at night and 
the patient discharged. The rest of the medication was kept at the 
same dose throughout the investigative period. Further visits at 
out-patients revealed that no further episodes of hypoglycaemia 
were occurring since reduction of lithium therapy, in spite of 
the steroids being tailed down. Lithium was eventually reduced 
to 200mg at night and steroids completely stopped on the 27th 
of April 2009. 
On the 15th of May 2009, the patient was admitted to hospital 
for a prolonged fasting test. He was advised not to eat anything 
between 4.00 pm and 8.00 am the following morning. He was 
allowed to drink water only. Blood glucose was monitored every 
hour. There were no low blood glucose readings. At 8.00 am, 
a 75g glucose oral drink was administered. Three hours later 
the patient suffered a symptomatic hypoglycaemic attack with 
blood glucose falling to 2.5mmo/L. The insulin level checked at 
this time was 11.0microU/ml (normal range 2.0-25.0microU/
ml),  C-peptide level was 3.73ng/ml (normal range 0.8-4.00ng/
ml) and proinsulin level was 61.7pmol/L (normal range 
6.4-9.4pmol/L). At this point, therefore, the patient was not 
having spontaneous hypoglyaemic episodes but had a late 
one precipitated by a glucose load. The lithium therapy was 
eventually tailed off by the end of June 2009. 
The prolonged fasting test was repeated on the 23rd of July 
2009. Serum lithium level was <0.10mmol/L (normal range 
0.6-1.5mmol/L), and this confirmed that the patient had indeed 
stopped lithium therapy as instructed. During the fast, the 
patient did not have hypoglycaemic episodes. At 8.00 am, a 75g 
glucose load was administered and the patient was observed for 
six hours later and was allowed to drink water only. Contrary to 
the first prolonged fasting test, the blood glucose estimations 
every 30 minutes were stable and there were no hypoglycaemic 
episodes after the glucose load. 
The patient is still being seen regularly at the hospital out-
patients department. He is well and has had no further problems 
since. A letter to the Medicine Authority has been sent reporting 
the adverse effects caused by lithium and diazoxide. 
Discussion
Lithium salts are used in the prophylaxis and treatment of 
mania, in the prophylaxis of bipolar disorders (manic-depressive 
disorder) and in the prophylaxis of recurrent depression 
(unipolar illness or unipolar depression). A literature search 
for the association of lithium therapy with hypoglycaemia did 
not reveal significant results. Pinelli et al reported neonatal 
hypoglycaemia with maternal lithium therapy, apart from 
Ebstein’s anomaly, cyanosis, rhythm disturbances and thyroid 
dysfunction.1 Shah et al performed five-hour oral glucose 
tests (OGTT) in nine patients receiving lithium therapy and 
in seven control patients.2  During GTT mean nadir serum 
glucose was significantly lower in the lithium-treated patients as 
compared to controls. The study suggested that chronic lithium 
treatment may be associated with symptomatic and biochemical 
hypoglycaemia during OGTT due to a rise in serum cortisol but 
lack of appropriate rise in plasma glucagon concentrations. 
Other hormonal effects were studied by Grof et al.3  In this study, 
lithium treatment resulted in a dramatic reduction in prolactin 
and growth hormone response to insulin hypoglycaemia. The 
reduced prolactin response to hypoglycaemia was also confirmed 
by Grof et al.4  However, other studies tend to contradict 
these findings. In the intact rat, lithium was found to inhibit 
glucose- and tolbutamide-induced insulin release, which in 
turn, causes glucose intolerance and prevents tolbutamide-
induced hypoglycaemia.5 The literature describes one report of a 
patient with lithium toxicity who presented with hypoglycaemia, 
acneform lesions, hypothyroidism and nephrogenic diabetes 
insipidus.6 However the case study presented above was not a 
case of lithium toxicity as was proved by repeated blood tests. 
The first oral glucose tolerance test also suggested a rebound 
type of hypoglycaemia. This could explain the fact that when the 
patient presented originally, his eating chocolate bars to alleviate 
a hypoglycaemic attack was in fact triggering the next one. The 
levels of pro-insulin were very high (up to 9 times the upper 
laboratory reference range). Pro-insulin has weak insulin-like 
biological activity of its own right, but a much longer half-life 
than insulin. It might therefore have contributed to a reactive-
type of hypoglycaemic reactions. A diagnostic problem which 
was encountered was the fact that the octreotide scan is not 
always helpful, since the false negative rate could reach up to 
50% due to different types of somatostatin receptors present in 
this tumour type.7,8,9 
The duration of the prolonged fasting tests might not be the 
recommended one, however in this case it served its purpose 
since the difference between the 2 tests occurred after the 
glucose challenge; when the patient was on lithium there was 
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severe hypoglycaemia and while off lithium the patient did not 
suffer any adverse events. So the two scenarios were directly 
comparable. Furthermore, stopping lithium therapy has resulted 
in the total absence of further hypoglycaemic episodes to date, 
virtually ruling out insulinomas since no definite treatment for 
these tumours was undertaken. Furthermore the patient has not 
developed other conditions e.g. diabetes mellitus.
It is clear that further studies need to be carried out in order 
to investigate the role of lithium in causing hypoglycaemia. 
However any patient on lithium suffering from recurrent 
episodes of hypoglycaemia may need a review of psychiatric 
treatment. 
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The Department of Obstetrics and Gynaecology within 
the Faculty of Medicine and Surgery has been the recipient 
of a simulation model aimed at assisting the development of 
clinical skills by medical students. The Zoe® Gynaecologic 
Simulator was kindly donated by Mr. Simon Delicata who is 
the local representative of the international-based company 
Bayer-Schering Pharma. The model consists of a full-sized 
Donation of a clinical-skills simulation model 
by Bayer-Schering Pharma
adult female lower torso designed as a training tool developed 
to assist health professionals to teach the processes and skills 
required to perform certain gynaecological procedures. 
Bayer Schering Pharma AG is an international healthcare 
company that is committed to sustainable development 
in various fields of healthcare including gynaecology. The 
present donation is a clear example of the commitment being 
shown by the company of the positive inter-relationship 
between industry and academia. The company has strongly 
supported the Department of Obstetrics and Gynaecology 
throughout the last years. It has set up the annual Bayer-
Schering Pharma Prize in Obstetrics & Gynaecology that is 
awarded to the student who obtains the highest aggregate 
mark in the speciality during the final examinations of the 
Medicine and Surgery course. In addition, the company has 
sponsored publications on the history of midwifery education 
and on the history of gynaecology in Malta prepared by the 
Department. The present gift is a welcome addition to the 
educational tools armamentarium of the Faculty since it helps 
augment the clinical skills simulation laboratories being set 
up by the Faculty.
